
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION**
Washington, D.C. 20549

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **January 8, 2024**

TREVENA, INC.
(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of incorporation)

001-36193
(Commission
File No.)

26-1469215
(IRS Employer
Identification No.)

**955 Chesterbrook Boulevard, Suite 110
Chesterbrook, PA 19087**
(Address of principal executive offices and zip code)

Registrant's telephone number, including area code: **(610) 354-8840**

Not applicable
(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, \$0.001 par value	TRVN	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Item 7.01 Regulation FD Disclosure

On January 8, 2024, Trevena, Inc. (the “Company”) updated its website to include an updated corporate presentation deck. A copy of the updated corporate deck is attached hereto as Exhibit 99.1.

The information set forth on this Item 7.01 and furnished hereto as Exhibits 99.1 shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and is not incorporated by reference into any of the Company’s filings under the Securities Act of 1933, as amended (the “Securities Act”) or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference in any such filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

<u>Number</u>	<u>Description</u>
<u>99.1</u>	<u>Corporate Presentation Deck dated January 8, 2024</u>
104	The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

SIGNATURES

Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TREVENA, INC.

Date: January 8, 2024

By: /s/ Barry Shin

Barry Shin

Senior Vice President & Chief Financial Officer



Nasdaq: TRVN | January 2024













Forward-Looking Statements

To the extent that statements contained in this presentation are not descriptions of historical facts regarding Trevena, Inc. (the “Company” or “we”), they are forward-looking statements reflecting management’s current beliefs and expectations. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry’s actual results, levels of activity, performance, or achievements to be materially different from those anticipated by such statements. You can identify forward-looking statements by terminology such as “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “might,” “plan,” “objective,” “predict,” “project,” “suggest,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” “ongoing,” or the negative of these terms or similar expressions. Forward-looking statements contained in this presentation include, but are not limited to, (i) statements regarding the timing of anticipated clinical trials for our product candidates; (ii) the timing of receipt of clinical data for our product candidates; (iii) our expectations regarding the potential safety, efficacy, or clinical utility of our product candidates; (iv) the size of patient populations targeted by our product candidates and market adoption of our potential drugs by physicians and patients; (v) the timing or likelihood of regulatory filings and approvals; and (vi) our cash needs.

Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the commercialization of any approved drug product, the status, timing, costs, results and interpretation of our clinical trials or any future trials of any of our investigational drug candidates; the uncertainties inherent in conducting clinical trials; expectations for regulatory interactions, submissions and approvals, including our assessment of the discussions with the FDA or other regulatory agencies about any and all of our programs; uncertainties related to the commercialization of OLINVYK; available funding; uncertainties related to our intellectual property; other matters that could affect the availability or commercial potential of our therapeutic candidates; and other factors discussed in the Risk Factors set forth in our Annual Report on Form 10-K and Quarterly Reports on Form 10-Q filed with the Securities and Exchange Commission (SEC) and in other filings we make with the SEC from time to time. In addition, the forward-looking statements included in this presentation represent our views only as of the date hereof. We anticipate that subsequent events and developments may cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, except as may be required by law.

Trevena's Experienced Leadership Team






SENIOR MANAGEMENT

Carrie L. Bourdow	Chair, President & Chief Executive Officer	 
Mark A. Demitrack, M.D.	SVP, Chief Medical Officer	  
Patricia Drake	SVP, Chief Commercial Officer	 
Barry Shin	SVP, Chief Financial Officer	  
Robert T. Yoder	SVP, Chief Business Officer & Head of Commercial Operations	 

BOARD OF DIRECTORS

Carrie L. Bourdow		Jake R. Nunn	 
Scott Braunstein, M.D. Lead Independent Director	  	Anne M. Phillips, M.D.	 
Mark Corrigan, M.D.	 	Barbara Yanni	
Marvin H. Johnson, Jr.			

Trevena: Innovative CNS Company

 IV OLINVYK: Differentiated profile	NCE approved for the management of acute pain in adults* Significant cost savings / differentiation shown in 'real world' post-approval studies
 TRV045: Selective S1PR modulator	S1PR: Validated target for blockbusters (fingolimod / siponimod / ozanimod / ponesimod) TRV045: Unique profile (with potential for no lymphopenia) for new indications
 TRV045: Compelling PoC Data	Statistically significant, dose-dependent effect in validated model of neuropathic pain Statistically significant EEG changes and evidence of early reduction in cortical excitability
 Novel CNS pipeline	New mechanisms for acute / neuropathic pain, epilepsy, acute migraine, opioid use disorder NCEs targeting significant unmet needs
 Financial position	\$35.0M cash / equivalents / marketable securities @ 3Q 23 Recent financing extends cash runway into 4Q 24

*OLINVYK is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Please see Important Safety Information including BOXED WARNING at the end of presentation.
Full Prescribing Information at www.OLINVYK.com

Multiple Expected Catalysts

	PRE-CLIN	PHASE 1	PHASE 2	PHASE 3	NDA	POST-APPR	Highlights
OLINVYK® New chemical entity (mu-opioid receptor)	IV acute pain*				APPROVED		<ul style="list-style-type: none"> Commercial launch ongoing
		Cleveland Clinic / Wake Forest Baptist Health collab.			VOLITION clinical outcomes		<ul style="list-style-type: none"> Real world differentiation
		Cleveland Clinic / Wake Forest Baptist Health collab.			ARTEMIS clinical outcomes		<ul style="list-style-type: none"> \$8.8k / 1.4 day savings
					Respiratory physiology		<ul style="list-style-type: none"> Data reported
					Cognitive function		<ul style="list-style-type: none"> Data reported
TRV045 Selective S1P receptor modulator		PoC – pain / target engagement					<ul style="list-style-type: none"> Data reported
		PoC - epilepsy					<ul style="list-style-type: none"> Data reported
		Seiz. Prev	NIH / ETSP investigating potential disease modifying role				<ul style="list-style-type: none"> Data expected 1Q 24
TRV734 G-protein selective agonist (mu-opioid receptor)		Opioid use disorder		NIH / NIDA collab.			<ul style="list-style-type: none"> POC study ongoing

*OLINVYK is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.OLINVYK.com




TRV045 and TRV734 are investigational products and are not approved by the FDA or any other regulatory agency
 NDA = New Drug Application; PoC = Proof-of-Concept

OLINVYK Overview

OLINVYK: Differentiated Profile for Acute Pain

OLINVYK is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate




Please see Important Safety Information including BOXED WARNING at the end of presentation.
Full Prescribing Information at www.OLINVYK.com.

VOLITION Clinical Outcomes Study w/ Cleveland Clinic

Further characterizes respiratory, GI and cognitive outcomes

- Open-label, multi-site study led by experts at Cleveland Clinic and Wake Forest Baptist Health
- N = 203 adults undergoing major non-cardiac surgery treated with IV OLINVYK



As reflected in the OLINVYK label, nausea and vomiting were two of the most common AEs reported in the controlled clinical trials

As with all opioids, serious, life-threatening, or fatal respiratory depression may occur in patients treated with OLINVYK

Sedation is an established risk of opioids including OLINVYK



Please see Important Safety Information including BOXED WARNING at the end of presentation
Full Prescribing Information at www.OLINVYK.com

ARTEMIS EMR-Based Clinical Outcomes Study

Statistically significant differentiation on a range of meaningful endpoints

- **201 OLINVYK-treated patients** at Cleveland Clinic and Wake Forest Baptist Health VOLITION sites
- **982 matched patients** undergoing similar surgical procedures, treated with other IV opioids, at same sites during VOLITION study

	Matched Patients Treated w/ other IV Opioids (N=982)		OLINVYK-Treated VOLITION Patients (N=201)	
Cost per Admission (avg)	\$45.9k	\$8.8k savings	\$37.1k	P<0.0001
Hospital Length of Stay (avg)	7.1 days	1.4 days shorter	5.7 days	P<0.0001
Numerical Pain Score (1-10)				
24hr mean score	4.5	15.0% lower score	3.9	P<0.0001
48hr mean score	4.3	14.8% lower score	3.7	P<0.0001

As with all opioids, addiction, abuse and misuse, which can lead to overdose and death may occur in patients treated with OLINVYK as indicated in the boxed warning

EMR analysis does not provide definitive data of group differences as seen in a prospectively randomized study



Please see Important Safety Information including BOXED WARNING at the end of presentation
Full Prescribing Information at www.OLINVYK.com

OLINVYK: Ease of Dosing and Administration

3 vials allow for flexible and tailored IV dosing

- **Bolus Dosing:** 1 mg and 2 mg vials (single dose)
- **PCA Dosing:** 30 mg vial (single patient use)
- **OLINVYK 1 mg \approx morphine 5 mg¹**

27 mg cumulative daily dose limit

Do not administer single doses greater than 3 mg

No refrigeration / reconstitution



1 mg / 1mL



2 mg / 2mL



30 mg / 30 mL

WAC:

\$17.50

\$25.75

\$110.00

~\$100 / day

(estimated avg cost across procedures)

Please see Important Safety Information including BOXED WARNING at the end of presentation. Full Prescribing Information at www.OLINVYK.com.

1) For an initial dose. PCA = Patient-Controlled Analgesia



TRV045
S1P Receptor Modulator
Novel MOA for Diabetic Neuropathic Pain

S1P₁ Receptor – Novel Target for CNS Indications

S1P₁ receptors are highly expressed on key CNS cells involved in neuroinflammation

Potential therapeutic role in seizures, epileptogenesis and pain signaling

Epilepsy

- Neuroprotective effects³
- Modulates BBB permeability, anti-inflammatory effects^{4,5}



Neuropathic pain

- Inhibits pain sensation¹
- Inhibits excitatory neuronal signaling²




Existing S1PR-targeted drugs, however, are ill-suited for CNS indications due to known:

Lymphopenia
Cardiac AEs

Pulmonary AEs
Ophthalmologic AEs

TRV045 MOA (1): Rapid Receptor Recycling

Maintained (rather than degraded) S1P receptors on cell surface




TRV045 MOA (2): S1PR Subtype-1 Selectivity

Subtype-1 is broadly expressed in the CNS and may avoid effects associated with other subtypes

- S1P acts on 5 distinct subtypes of receptors (S1P₁₋₅)
- TRV045 is **potent and selective for S1P subtype-1 receptor**
 - S1P₁R is highly expressed on astrocytes / other glial cells
 - May play role in central pain signaling, as well as development and persistence of seizures

Highly expressed in key
CNS / brain cells




TRV045 MOA (3): Anti-Inflammatory Effect (nonclinical)

Anti-inflammatory actions (cytokines / chemokines) on astrocytes in cell culture

- **Main Findings:** Net anti-inflammatory action (statistically significant) on astrocyte cytokine / chemokine release
 - Increased all **anti-inflammatory** markers measured¹
 - Reduced all **inflammatory** markers measured¹
- **Method:** Primary mouse astrocytes in monolayer cell culture, incubated for 24hrs w/ 5 μ M TRV045
 - 17 cytokines / chemokines² assessed by ELISA

TRV045-affected cytokines / chemokines play a role in many CNS disorders
(epilepsy, pain, neuropsych / neurodegen diseases)



1) P<0.05 v vehicle

2) Full cytokine / chemokine panel studied: (Inflammatory markers) – TNFa, IL-6, IL-1b, IL-17, IL-23, IL-33, CCL1, CCL2, CCL20, CXCL5, CXCL12, CX3CL1, IFNg, Csf2, Substance P; (Anti-inflammatory markers) – IL-10, IL-4. (Trevena, Inc., data on file)

TRV045 Proof-of-Concept Study Program – Highlights

Preliminary data*

- **Target Engagement.** Demonstrated CNS penetration and target engagement
- **Neuropathic Pain.** Statistically significant, dose-dependent effect in validated model of neuropathic pain
- **EEG Spectral Power.** Statistically significant **increases** in brain waves (alpha, beta, gamma) associated with arousal, alertness, cognitive processing, learning and memory

Statistically significant **decrease** in delta brain waves, and **no significant change** in theta brain waves, both of which are associated with sedation / sleep

- **Cortical Excitability.** Directional evidence of early reduction in cortical excitability


Not all of the results were statistically significant;
details of the findings are presented on the following slides



Studies were conducted outside the United States and not under the IND for TRV045

Target Engagement (PainCart®) POC Study Design

- **Design:** Randomized, double-blind, placebo-controlled, single dose, four-way cross-over (N=25 subjects; 8F/17M, mean age 37.6 years, range 18-53)
 - Placebo or TRV045 (50/150/300mg)



- **Pharmacodynamic Endpoints:**
 - Mechanical allodynia (Von Frey hair testing on capsaicin-treated skin), pressure pain, heat pain (capsaicin-treated, UVB-exposed, and unexposed skin), cold pain (CPT), electrical pain (stair, burst conditions), conditioned pain modulation (electrical pain pre- and post-CPT)
- PK exposure parameters (C_{max} , $t_{1/2}$)
- Safety and tolerability



Studies were conducted outside the United States and not under the IND for TRV045
Source: Trevena data on file


TRV045 Significantly Reduced Mechanical Allodynia

1% capsaicin-treated dominant volar forearm – Von Frey filament allodynic area (CFB, mm²)


300mg TRV045 v Placebo; P=0.0023
150mg TRV045 v Placebo; P=0.0022

300mg TRV045 v Placebo; P=0.0001
150mg TRV045 v Placebo; P=0.0002


Secondary Allodynic Area



Total Allodynic Area



Effect Size Comparison: TRV045 v Other Analgesics



Effect Size:
 +0.2 – small effect
 +0.5 – medium effect
 +0.8 – large effect

- Studies for comparators conducted at same lab (CHDR) conducting TRV045 studies
- Single highest result for each comparator provided (cold pressor) from a battery of CHDR tests conducted
 - Mechanical allodynia test was not conducted on comparators


Target Engagement (PainCart®) Study

PainCart observations

- Statistically significant, dose-dependent, treatment effect in model of capsaicin-induced mechanical allodynia provides evidence of the therapeutic potential of TRV045 in neuropathic pain
 - Recognized and validated study index of central pain processing ('central sensitization')
 - Note that effect appeared similar with both 150mg and 300mg dose, potentially guiding future decisions on dose range for use in Phase 2
- Supportive evidence of analgesic action in select other nociceptive models
 - Other endpoints did not show trend / statistically significant results (pressure pain / conditioned pain modulation)
- Overall, strong support for CNS penetrance and engagement of pain signaling pathways in the brain
 - PK exposure consistent with parameters observed at comparable doses studied under fed conditions in Phase 1 FIH study
- No SAEs, no drug-related study discontinuations

TMS POC Study Design

- **Design:** Randomized, double-blind, placebo-controlled, multiple dose, two-way cross-over (n=25 male subjects; mean age 31.5 years, range 21-55)
 - Placebo or TRV045 (250mg) for 4 days; post-dose assessments performed at 4 hours






- TMS-EEG Pharmacodynamic endpoints:
 - Resting qEEG power spectral analysis (eyes open/eyes closed): Alpha, Beta, Delta, Gamma, Theta bands
 - TMS-evoked EEG response (single and paired-pulse TMS)
- TMS-EMG Pharmacodynamic endpoints:
 - Motor-evoked potential (MEP), resting motor threshold (single pulse TMS), paired-pulse TMS



Studies were conducted outside the United States and not under the IND for TRV045
TMS = Transcranial magnetic stimulation
Source: Trevena data on file

EEG Shifts in Alpha, Beta, Gamma, Delta Power Spectra

Resting qEEG Power Spectral Analysis – Eyes Open, Day 4 TRV045 v Placebo All Bands



Alpha: Significant increase across all regions
Beta/Gamma: Significant increase in frontal region
Delta: Significant reduction in right parietal region
Theta: No significant difference

associated with alertness / arousal
memory / learning

associated with sedation / sleep




* Denotes pairwise comparison $P < 0.05$
 Frontal = Fz-Cz; left parietal = Pz-O1; right parietal = PzO2
 CFB = change from baseline; Source: Trevena data on file

Mantini, D, et al. PNAS (2007); Beste, C, et al. Nature Comm Biol (2023);
 Edwards, DJ and Trujillo, LT, Brain Sci (2021); Holler, Y, et al., CNS Drugs (2018)²²


TRV045 Effect on Cortical Excitability vs AEDs*

Mean change from baseline in motor-evoked potential (MEP) measured by peak-to-peak amplitude



Est. difference TRV045 v placebo (not stat. sig.)

- 304.14 µV, 95% CI -688.19 to 79.919 (P=0.1182)



Estimated difference vs placebo:

- Levetiracetam: -378.4 µV, 95% CI -644.3 to -112.5; P<0.01
- Valproic acid: -268.8 µV, 95% CI -532.9 to -4.6; P=0.047
- Lorazepam: -330.7.4 µV, 95% CI -595.6 to -65.8; P=0.02

Mean change from baseline in MEP on Day 1 with TRV045 comparable in magnitude to MEP reductions seen with known AEDs, including levetiracetam, valproic acid, and lorazepam, performed in the same laboratory

Safety and Tolerability Summary

POC data generally consistent with FIH study

- No AEs assessed as probably / definitely related to study drug; no AEs reported as severe; no SAEs
 - 98% of AEs (102 of 104) in PainCart® study reported as mild
 - 99% of AEs (79 of 80) in TMS study reported as mild
- Screening / follow-up physical exams (including ophthalmologic exams) with no clinically significant findings
- Lab results showed **no drug-related**:
 - Reduction in total lymphocyte count
 - Changes in heart rate or blood pressure
 - Changes in ECG interval measures
(no prolongation of PR or QTcF intervals)

Safety and Tolerability Summary

Generally well tolerated and consistent with FIH study

- AEs with incidence of $\geq 10\%$ for any TRV045 dose shown below (none deemed drug related)

PainCart Study		Placebo		TRV045 50mg		TRV045 150mg		TRV045 300mg	
		N (%)	Events	N (%)	Events	N (%)	Events	N (%)	Events
General Disorders	Fatigue	3 (12%)	3	1 (4%)	1	3 (12%)	3	2 (8%)	2
Nervous System Disorders	Dizziness	2 (8%)	2	0	0	3 (12%)	3	3 (12%)	3
	Headache	2 (8%)	2	3 (12%)	3	8 (32%)	9	8 (32%)	9
	Somnolence	2 (8%)	3	2 (8%)	2	5 (20%)	5	8 (32%)	8

TMS Study		Placebo		TRV045 250mg	
		N (%)	Events	N (%)	Events
General Disorders	Fatigue	1 (4%)	3	3 (12%)	5
Nervous System Disorders	Headache	6 (22%)	8	9 (36%)	12
	Somnolence	4 (15%)	3	3 (12%)	4

- No clinically significant difference (vs placebo) in any AEs including:

Sedation	Balance Disorders	Attention Disturbances
Nausea	Dry Mouth	Blurred Vision

Overall Conclusions

TRV045 Proof-of-Concept Study Program

Taken together, these two POC studies provide strong support and direction for future development of TRV045

- **Target Engagement.** Demonstrated CNS penetration and target engagement
- **Neuropathic Pain.** Statistically significant, dose-dependent effect in validated model of neuropathic pain
- **Epilepsy.** Promising evidence of early reduction in cortical excitability
Statistically significant **increases** in brain waves (alpha, beta, gamma) associated with arousal, alertness, cognitive processing, learning and memory
Statistically significant **decrease** in delta brain waves, and **no significant change** in theta brain waves, which are both associated with sedation / sleep
- **Differentiated Profile.** Novel MOA; expected once-daily oral dosing; potentially effective with favorable safety / tolerability

TRV045: Broad Potential Applicability

Unique MOA Produces Compelling Profile

Potent and selective S1P₁R target engagement
anti-inflammatory and nociceptive effects

No lymphopenia (in FIH study)
potentially limits other S1PR modulators

May avoid AEs associated with approved S1PR drugs
cardiac / pulmonary / ophthalmologic

Potential fields for development may include:

Seizure treatment (anticonvulsant)

Prevention of seizure (epileptogenesis) ←






potential disease-modifying MOA

Pain (DPN, CIPN)

Autoimmune (MS, RA, UC, Crohn's Disease)

Neuropsychiatric / neurodegenerative (MDD, schizophrenia, AD, PD)

Trevena: Innovative CNS Company

 IV OLINVYK: Differentiated profile	NCE approved for the management of acute pain in adults* Significant cost savings / differentiation shown in 'real world' post-approval studies
 TRV045: Selective S1PR modulator	S1PR: Validated target for blockbusters (fingolimod / siponimod / ozanimod / ponesimod) TRV045: Unique profile (with potential for no lymphopenia) for new indications
 TRV045: Compelling PoC Data	Statistically significant, dose-dependent effect in validated model of neuropathic pain Statistically significant EEG changes and evidence of early reduction in cortical excitability
 Novel CNS pipeline	New mechanisms for acute / neuropathic pain, epilepsy, acute migraine, opioid use disorder NCEs targeting significant unmet needs
 Financial position	\$35.0M cash / equivalents / marketable securities @ 3Q 23 Recent financing extends cash runway into 4Q 24

*OLINVYK is indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate. Please see Important Safety Information including BOXED WARNING at the end of presentation.
Full Prescribing Information at www.OLINVYK.com



IMPORTANT SAFETY INFORMATION



WARNING: ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and RISKS FROM CONCOMITANT USE WITH BENZODIAZEPINES OR OTHER CENTRAL NERVOUS SYSTEM (CNS) DEPRESSANTS

Addiction, Abuse, and Misuse

OLINVYK exposes patients and other users to the risks of opioid addiction, abuse, and misuse, which can lead to overdose and death. Assess each patient's risk before prescribing OLINVYK, and monitor all patients regularly for the development of behaviors or conditions.

Life-Threatening Respiratory Depression

Serious, life-threatening, or fatal respiratory depression may occur with use of OLINVYK. Monitor for respiratory depression, especially during initiation of OLINVYK or following a dose increase.

Neonatal Opioid Withdrawal Syndrome

Prolonged use of OLINVYK during pregnancy can result in neonatal opioid withdrawal syndrome, which may be life-threatening if not recognized and treated, and requires management according to protocols developed by neonatology experts. If opioid use is required for a prolonged period in a pregnant woman, advise the patient of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.

Risk From Concomitant Use With Benzodiazepines or Other CNS Depressants

Concomitant use of opioids with benzodiazepines or other CNS depressants, including alcohol, may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing for use in patients for whom alternative treatment options are inadequate; limit dosages and durations to the minimum required; and follow patients for signs and symptoms of respiratory depression and sedation.

Limitations of Use

Because of the risks of addiction, abuse, and misuse with opioids, even at recommended doses, reserve OLINVYK for use in patients for whom alternative treatment options [e.g., non-opioid analgesics or opioid combination products]:

- Have not been tolerated, or are not expected to be tolerated
 - Have not provided adequate analgesia, or are not expected to provide adequate analgesia.
- The cumulative total daily dose should not exceed 27 mg, as total daily doses greater than 27 mg may increase the risk for QTc interval prolongation.

CONTRAINDICATIONS

OLINVYK is contraindicated in patients with:

- Significant respiratory depression
- Acute or severe bronchial asthma in an unmonitored setting or in the absence of resuscitative equipment
- Known or suspected gastrointestinal obstruction, including paralytic ileus
- Known hypersensitivity to oliceridine (e.g., anaphylaxis)

WARNINGS AND PRECAUTIONS

- OLINVYK contains oliceridine, a Schedule II controlled substance, that exposes users to the risks of addiction, abuse, and misuse. Although the risk of addiction in any individual is unknown, it can occur in patients appropriately prescribed OLINVYK. Assess risk, counsel, and monitor all patients receiving opioids.
- Serious, life-threatening respiratory depression has been reported with the use of opioids, even when used as recommended, especially in patients with chronic pulmonary disease, or in elderly, cachectic and debilitated patients. The risk is greatest during initiation of OLINVYK therapy, following a dose increase, or when used with other drugs that depress respiration. Proper dosing of OLINVYK is essential, especially when converting patients from another opioid product to avoid overdose. Management of respiratory depression may include close observation, supportive measures, and use of opioid antagonists, depending on the patient's clinical status.
- Opioids can cause sleep-related breathing disorders including central sleep apnea (CSA) and sleep-related hypoxemia with risk increasing in a dose-dependent fashion. In patients who present with CSA, consider decreasing the dose of opioid using best practices for opioid taper.

INDICATIONS AND USAGE

OLINVYK is a new chemical entity indicated in adults for the management of acute pain severe enough to require an intravenous opioid analgesic and for whom alternative treatments are inadequate.



WARNINGS AND PRECAUTIONS

- Prolonged use of opioids during pregnancy can result in withdrawal in the neonate that may be life-threatening. Observe newborns for signs of neonatal opioid withdrawal syndrome and manage accordingly. Advise pregnant women using OLINVYK for a prolonged period of the risk of neonatal opioid withdrawal syndrome and ensure that appropriate treatment will be available.
- Profound sedation, respiratory depression, coma, and death may result from the concomitant use of OLINVYK with benzodiazepines or other CNS depressants (e.g., non-benzodiazepine sedatives/hypnotics, anxiolytics, tranquilizers, muscle relaxants, general anesthetics, antipsychotics, other opioids, or alcohol). Because of these risks, reserve concomitant prescribing of these drugs for use in patients for whom alternative treatment options are inadequate, prescribe the lowest effective dose, and minimize the duration.
- OLINVYK was shown to have mild QTc interval prolongation in thorough QT studies where patients were dosed up to 27 mg. Total cumulative daily doses exceeding 27 mg per day were not studied and may increase the risk for QTc interval prolongation. Therefore, the cumulative total daily dose of OLINVYK should not exceed 27 mg.
- Increased plasma concentrations of OLINVYK may occur in patients with decreased Cytochrome P450 (CYP) 2D6 function or normal metabolizers taking moderate or strong CYP2D6 inhibitors; also in patients taking a moderate or strong CYP3A4 inhibitor, in patients with decreased CYP2D6 function who are also receiving a moderate or strong CYP3A4 inhibitor, or with discontinuation of a CYP3A4 inducer. These patients may require less frequent dosing and should be closely monitored for respiratory depression and sedation at frequent intervals. Concomitant use of OLINVYK with CYP3A4 inducers or discontinuation of a moderate or strong CYP3A4 inhibitor can lower the expected concentration, which may decrease efficacy, and may require supplemental doses.
- Cases of adrenal insufficiency have been reported with opioid use (usually greater than one month). Presentation and symptoms may be nonspecific and include nausea, vomiting, anorexia, fatigue, weakness, dizziness, and low blood pressure. If confirmed, treat with physiologic replacement doses of corticosteroids and wean patient from the opioid.
- OLINVYK may cause severe hypotension, including orthostatic hypotension and syncope in ambulatory patients.
- There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics). Monitor these patients for signs of hypotension. In patients with circulatory shock, avoid the use of OLINVYK as it may cause vasodilation that can further reduce cardiac output and blood pressure.
- Avoid the use of OLINVYK in patients with impaired consciousness or coma. OLINVYK should be used with caution in patients who may be susceptible to the intracranial effects of CO₂ retention, such as those with evidence of increased intracranial pressure or brain tumors, as a reduction in respiratory drive and the resultant CO₂ retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy.
- As with all opioids, OLINVYK may cause spasm of the sphincter of Oddi, and may cause increases in

serum amylase. Monitor patients with biliary tract disease, including acute pancreatitis, for worsening symptoms.

- There is increased risk in patients whose ability to maintain blood pressure has already been compromised by a reduced blood volume or concurrent administration of certain CNS depressant drugs (e.g., phenothiazines or general anesthetics). Monitor these patients for signs of hypotension. In patients with circulatory shock, avoid the use of OLINVYK as it may cause vasodilation that can further reduce cardiac output and blood pressure.
- Avoid the use of OLINVYK in patients with impaired consciousness or coma. OLINVYK should be used with caution in patients who may be susceptible to the intracranial effects of CO₂ retention, such as those with evidence of increased intracranial pressure or brain tumors, as a reduction in respiratory drive and the resultant CO₂ retention can further increase intracranial pressure. Monitor such patients for signs of sedation and respiratory depression, particularly when initiating therapy.
- As with all opioids, OLINVYK may cause spasm of the sphincter of Oddi, and may cause increases in serum amylase. Monitor patients with biliary tract disease, including acute pancreatitis, for worsening symptoms.
- OLINVYK may increase the frequency of seizures in patients with seizure disorders and may increase the risk of seizures in vulnerable patients. Monitor patients with a history of seizure disorders for worsened seizure control.
- Do not abruptly discontinue OLINVYK in a patient physically dependent on opioids. Gradually taper the dosage to avoid a withdrawal syndrome and return of pain. Avoid the use of mixed agonist/antagonist (e.g., pentazocine, nalbuphine, and butorphanol) or partial agonist (e.g., buprenorphine) analgesics in patients who are receiving OLINVYK, as they may reduce the analgesic effect and/or precipitate withdrawal symptoms.
- OLINVYK may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car or operating machinery.
- Although self-administration of opioids by patient-controlled analgesia (PCA) may allow each patient to individually titrate to an acceptable level of analgesia, PCA administration has resulted in adverse outcomes and episodes of respiratory depression. Health care providers and family members monitoring patients receiving PCA analgesia should be instructed in the need for appropriate monitoring for excessive sedation, respiratory depression, or other adverse effects of opioid medications.

ADVERSE REACTIONS

Adverse reactions are described in greater detail in the Prescribing Information.

The most common (incidence $\geq 10\%$) adverse reactions in Phase 3 controlled clinical trials were nausea, vomiting, dizziness, headache, constipation, pruritus, and hypoxia.

PLEASE see www.OLINVYK.com for full prescribing information including **BOXED warning and important safety information**